Innate Pharma to Participate in the Kempen Life Sciences Conference
Innate Pharma announced that senior executives will hold one‑on‑one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15‑16, 2026. The biotech firm will use the event to showcase its pipeline, including the Nectin‑4 ADC IPH4502, the anti‑KIR3DL2 antibody Lacutamab, and the AstraZeneca‑partnered anti‑NKG2A antibody Monalizumab. Innate highlighted its collaborations with AstraZeneca and Sanofi and reiterated its dual listing on Euronext Paris and Nasdaq. The press release underscores the company’s focus on expanding investor engagement ahead of key clinical milestones.
PTSD Is Almost Incurable. Psychedelics Can Help — but only in Three U.S. States and Australia
Australia has opened a regulated pathway for MDMA‑assisted psychotherapy to treat post‑traumatic stress disorder, making it one of the few countries where the drug can be used medically. Early data from Dr. Ranil Gunewardene’s practice show more than 50 % of...
Anthropic Buys Stealth Dimension-Backed Coefficient Bio in $400M+ Stock Deal
Anthropic has acquired stealth biotech startup Coefficient Bio in a stock transaction valued at just over $400 million. Coefficient Bio, founded eight months ago, develops AI models aimed at accelerating biological research and pursuing artificial superintelligence for science. The deal brings...
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. Difficile Infection Will Continue...
Vedanta Biosciences announced that the independent Data Monitoring Committee has completed the first prespecified interim analysis of its Phase 3 RESTORATiVE303 trial and recommended the study continue unchanged. The interim data showed efficacy surpassing the futility threshold with no new safety...
SV Health Investors Acquires EpiVax
SV Health Investors (SVHI) announced the acquisition of EpiVax, a Providence‑based bioanalytical CRO that specializes in immunogenicity risk assessments for pharma and biotech firms. The deal adds a proven scientific platform, including the ISPRI predictive software and cell‑based assays, to...
Boston University to Apply Machine Learning to Alzheimer’s Biomarker and Cognitive Data
Boston University, leading the AI for Alzheimer’s Disease (AI4AD) consortium, is coordinating 11 research institutes to apply machine learning to massive genomic, biomarker and cognitive datasets. The team is building the PreSiBO database, which tags predictor, signature, biomarker and outcome...
Pharmaceutical Giant Pfizer Forced To Shut Down Updated COVID Vaccine Trials
Pfizer announced it is halting development of its updated COVID‑19 vaccine candidates, ending ongoing Phase 2/3 trials that targeted newer variants. The decision follows mixed efficacy data and waning commercial demand as the pandemic recedes. Pfizer will redirect resources toward...
TRPM3: The Ion Channel Behind Pain, Migraines, and ME/CFS
TRPM3 is a calcium‑permeable ion channel activated by heat and neurosteroids such as pregnenolone sulfate, playing a central role in pain perception, insulin secretion, and vascular regulation. Genetic variants in the TRPM3 gene have been associated with heightened susceptibility to...
Pfizer Halts COVID Shot Trial Because They Can’t Find Enough Test Subjects Willing to Take Another Booster Shot
Pfizer and BioNTech have halted a large U.S. clinical trial of an updated COVID‑19 booster after failing to enroll enough healthy adults aged 50‑64. The study required tens of thousands of participants, but recruitment stalled amid a sharp decline in...
Asundexian
Bayer’s oral factor XIa inhibitor asundexian (BAY 2433334) has delivered positive Phase 3 data in the OCEANIC‑STROKE trial, positioning it as a potential first‑in‑class therapy for secondary stroke prevention. The drug aims to block pathological clot formation while minimizing the bleeding complications common...
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava
Shionogi completed a $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding an approved ALS treatment to its portfolio. The deal transfers all intellectual property, sales rights and the existing commercial team, delivering an estimated $700 million in annual...
NR0B2 Is Protective of Cartilage, But Expression Decreases as Osteoarthritis Progresses
Researchers identified the orphan nuclear receptor NR0B2 (also known as SHP) as a protective factor in cartilage, with its expression markedly reduced in osteoarthritic tissue. In male mice, global or chondrocyte‑specific deletion of Nr0b2 worsened pain and joint damage after...
Pharma Pulse: Foundayo’s FDA Approval and the Strategic Risk of Pharmacy Data Consolidation
Eli Lilly’s Foundayo became the first new molecular entity approved under the FDA’s National Priority Voucher pilot, clearing in a record 50 days. It is the only GLP‑1 weight‑loss pill that can be taken without food or water restrictions, aiming to...
What Will Approval of Foundayo GLP-1 Tablets Bring?
The FDA has approved Foundayo (orforglipron), the first non‑peptide oral GLP‑1 tablet for obesity. As a small‑molecule drug, it sidesteps the manufacturing complexities that plagued peptide injectables like semaglutide and tirzepatide. Daily oral dosing promises easier adherence compared with weekly...
What Didn’t Exist Three Years Ago
The American Association for Cancer Research (AACR) annual meeting highlighted the latest direction of early‑stage drug development. This year’s sessions featured two prostate‑cancer candidates using mechanisms that were not in the clinic just eighteen months ago. The preview spotlights a...
Novel Therapeutic and Trial Approaches for Lysosomal Storage Disorders with Polaryx’s Alex Yang — Episode 249
In episode 249 of the Xtalks Life Science Podcast, Alex Yang, JD, LLM, CEO of Polaryx, discusses the company’s mission to develop disease‑modifying small‑molecule therapies for rare pediatric lysosomal storage disorders. Yang leverages more than 25 years of experience across...
Loargys (Pegzilarginase) Wins FDA Nod for Ultrarare Metabolic Disorder After Earlier Setbacks
The U.S. FDA granted accelerated approval to Loargys (pegzilarginase‑nbln) for treating arginase‑1 deficiency (ARG1‑D), an ultrarare metabolic disorder affecting roughly 250 Americans. Loargys, a recombinant human arginase‑1 enzyme, is the first therapy shown to lower plasma arginine levels, achieving about...
Nanotechnology Sensor Reads Creatinine in Seconds for Rapid Kidney Testing
Researchers at Tohoku University and City College of New York unveiled a nanotechnology‑based creatinine biosensor that reads concentrations from 1 to 300 mg/dL in about 35 seconds. The device uses a platinum‑nanoparticle polymer composite tuned near the percolation threshold, eliminating the...
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
The Trump administration has postponed filing an appeal against a federal judge’s injunction on RFK Jr.’s vaccine policy overhaul, citing internal debates over election‑year politics. Meanwhile, Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a premium of...
Being Specific About Being General: Vaccines Edition
Emerging platforms are converging on a universal influenza vaccine, aiming to replace strain‑specific shots that require yearly reformulation. Companies such as Versatope are leveraging engineered bacterial outer‑membrane vesicles to deliver precise antigens, while NIH’s FluMos‑v2 expands hemagglutinin coverage to six...
A Deep Dive Into INN Proposed List 134
The World Health Organization released its International Nonproprietary Names (INN) Proposed List 134, introducing 124 new drug names slated for future approval. The list features a notable influx of antiviral and oncology agents, as well as the first biosimilar designations...
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of...
Vertex Pharmaceuticals announced that the U.S. FDA has approved label expansions for its CFTR modulators ALYFTREK and TRIKAFTA. ALYFTREK is now indicated for patients six years and older whose CFTR gene produces any functional protein, while TRIKAFTA’s indication now includes...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with...
Zai Lab and Amgen have entered a global collaboration to test Zai Lab’s DLL3‑targeting antibody‑drug conjugate, zocilurtatug pelitecan (zoci), together with Amgen’s FDA‑approved bispecific T‑cell engager IMDELLTRA® in extensive‑stage small cell lung cancer (ES‑SCLC). Amgen will sponsor and lead a...
The New Infrastructure of Drug Commercialization
The pharmaceutical commercialization landscape is undergoing a rapid overhaul, driven by heightened government pricing controls, the rise of complex biologics, cell and gene therapies, and advanced data systems. Cold‑chain logistics have become a strategic priority as temperature‑sensitive products proliferate, while...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics and privately‑held Korsana Biosciences have signed an all‑stock merger agreement, creating a combined company that will operate as Korsana Biosciences and trade on Nasdaq under the ticker KRSA. Korsana secured an oversubscribed $380 million private placement that will fund...
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
Amprion announced a strategic partnership with Macquarie University to launch Australia’s first clinical alpha‑synuclein seed amplification testing site, expanding its global footprint. The company will continue collaborative research with the Michael J. Fox Foundation in 2026, integrating its SAAmplify‑ɑSYN assay into...
Smart Drugs Are Here
A recent proof‑of‑concept study introduces DNA‑drug conjugates (DDCs) that turn “smart drugs” into programmable therapies. DDCs use split DNA strands as logic gates to release payloads only when specific biomarker combinations are present, offering higher specificity than antibody‑drug conjugates (ADCs)....
The Biotech Bi-Weekly: Cell Barcoding, Compound Optimization and the Trillion Cell Atlas
The biotech sector is witnessing a wave of collaborations and product launches aimed at accelerating drug discovery and expanding genomic knowledge. Biotium introduced the ViaPlex™ 2‑Color Cell Barcoding Kit, enabling multiplex analysis of up to 15 cell populations in a...
Smart IUD Could ‘Provide Insights We’ve Never Had Before’
Verso Biosense, based in Oxfordshire, is creating a wireless smart IUD that continuously records uterine temperature and oxygen levels. The device aims to generate real‑time data to help clinicians understand why some IVF cycles fail and to identify conditions that...
Remaining Challenges in the Development of Partial Reprogramming Therapies
Partial reprogramming—brief exposure to Yamanaka factors OCT4, SOX2, KLF4 and MYC—has demonstrated modest rejuvenation in mouse studies but carries a substantial cancer risk if cells slip into full pluripotency. Funding is concentrated in a few well‑capitalized firms, notably Altos Labs,...
Productivity Enhancing Bioreactor for Scalable Organoid Culture
AMSBIO introduced RPMotion, a spinning organoid bioreactor that accelerates and automates 3‑D cell culture for drug discovery, disease modeling and regenerative medicine. The system delivers up to five‑fold faster organoid expansion while cutting reagent costs by roughly 60% and labor...
Boston Scientific Receives FDA Clearance for the Asurys Fluid Management System
Boston Scientific announced FDA 510(k) clearance for its Asurys Fluid Management System, a device that provides automated irrigation and intrarenal pressure control during endoscopic urologic procedures such as ureteroscopy. The system integrates with the LithoVue Elite single‑use digital ureteroscope, allowing...
Regulating Payment of Participant Data in Clinical Trials
A team of scholars led by Steve Calandrillo proposes that FDA and IRBs adopt fair‑market‑value (FMV) payments for the data participants generate in clinical trials. Currently, participants receive modest compensation—about $4,000 per year—solely for trial involvement, not for the valuable...
BREAKING STUDY: Half of COVID-19 Vaccinated Military Personnel Suffered Subclinical Heart Stress
A new longitudinal study of 83 healthy military personnel tracked cardiac biomarkers after two mRNA COVID‑19 vaccine doses. Within two weeks of the second shot, 49% of participants exhibited a rise in NT‑proBNP exceeding 1.5 times their baseline, indicating subclinical...
AZD5004
Elecoglipron (ECC5004/AZD5004), an oral small‑molecule GLP‑1 receptor agonist, completed Phase 2 trials in type 2 diabetes and obesity, meeting primary endpoints in the SOLSTICE and VISTA studies. AstraZeneca licensed global rights from Eccogene for an upfront payment of $185 million and potential milestones...
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed...
CellCentric has launched the pivotal Phase 2 DOMMINO‑1 trial of inobrodib 20 mg combined with pomalidomide and dexamethasone (InoPd) in heavily pretreated relapsed or refractory multiple myeloma (RRMM) patients. The first dose was administered at The Royal Marsden in London, with additional...
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion...
ImmunityBio secured $75 million of non‑dilutive financing under its existing royalty‑interest purchase agreement with Oberland Capital, raising total committed capital to $375 million. At the same time, Nant Capital converted $25 million of debt into common stock, reducing the company’s liabilities. The combined...
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium Abscessus Complex Lung Disease
AN2 Therapeutics has begun a Phase 2 investigator‑initiated trial of epetraborole, an oral leucyl‑tRNA synthetase inhibitor, for pulmonary disease caused by Mycobacterium abscessus. The randomized, double‑blind study will enroll 84 patients across roughly 10‑15 U.S. sites and is led by Dr. Kevin...
Is AI Ready to Transform COA Development?
Artificial intelligence is reshaping clinical development by augmenting, not replacing, human expertise. AI already accelerates medical imaging, compound discovery and COVID‑19 vaccine modeling, compressing timelines from years to months. In clinical outcome assessment (COA) translation, AI can support draft translation...
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Natera’s Signatera circulating‑tumor DNA test was shown in a prospective Clinical Cancer Research study to identify older women (≥70) with early‑stage ER⁺/HER2‑ breast cancer who can safely forgo surgery and remain progression‑free on primary endocrine therapy. Baseline MRD‑negative patients (68%...
NVIDIA’s Healthcare Stack Is the Picks and Shovels Play You’ve Been Waiting For
NVIDIA has assembled a comprehensive AI infrastructure stack for healthcare, encompassing BioNeMo, MONAI, Isaac for Healthcare, Holoscan, Parabricks, Clara and NIM. Its 2026 State of AI in Healthcare survey shows 70% of organizations actively using AI, with generative models now...
The Ways Pharma Leaders Are Rewiring Their Organizations for Launch Success
Pharma executives face mounting pressure to deliver faster, more successful product launches amid volatile markets and tighter timelines. Inizio Ignite’s Global President Remco op den Kelder argues that traditional static launch plans must give way to agile, data‑driven execution models....
Dose by Design: Pharmaceutical 3D Printing and the Future of Pediatric Compounding
The article charts the transition of pharmaceutical 3D printing from research pilots to routine pharmacy practice, focusing on pediatric compounding. Companies such as FabRx and CurifyLabs have built platforms that let pharmacists print chewable tablets, gels, and mini‑tablets tailored to...
Women’s Hereditary Cancer Testing: From Specialist to Self-Refer
Direct‑to‑consumer genetic testing is reshaping how women assess hereditary cancer risk, allowing them to bypass the traditional NHS referral pathway that required GP and genetics team approval. Private providers such as Jeen Health now offer clinically validated panels via at‑home...
A Gut Microbiome Response to Low Protein Intake Drives Beneficial Browning of Fat Tissue
Researchers have shown that low‑protein diets (LPDs) stimulate the conversion of white adipose tissue into thermogenic beige fat, mirroring effects seen with cold exposure or β‑adrenergic activation. The browning response depends on specific gut microbes; germ‑free mice fail to brown,...
Can Damage to a Stressed Cell Be Reversed?
Soley Therapeutics’ co‑founder and CEO Dr. Yerem Yeghiazarians explained the company’s novel strategy of using small‑molecule drugs to reverse cellular stress rather than targeting a specific virus or gene. The platform aims to restore function in stressed cells implicated in non‑oncology...
Healing Wounded Skin without Scarring? Preclinical Research Shows Promise
Harvard researchers uncovered that post‑natal skin scarring is driven by fibroblast‑produced Cxcl12, which triggers excessive nerve growth that blocks full tissue regeneration. By deleting Cxcl12 or applying Botox to suppress local nerve signaling, mice healed wounds without scars, restoring all...
Right Through the Skull
Researchers have unveiled a novel calvarial delivery platform that injects drug‑laden nanoparticles into the skull’s bone marrow. Immune cells within the diploic space capture the particles and migrate across skull‑meninges channels, ferrying the therapeutic cargo into the brain. In mouse...
Cost of Cultured Meat: Workshop, Modeling, Resources, Feedback
The Unjournal is hosting an online workshop in late April/early May 2026 to refine cost projections for cultivated meat, especially cultured chicken, using an interactive Monte Carlo model. Participants—including bioprocess engineers, cell biologists, animal‑welfare funders, and industry practitioners—will shape belief‑elicitation surveys...
Efforts to Treat Neurodegenerative Disease by Altering the Gut Microbiome
Research increasingly shows that gut microbiome composition influences brain health, with age‑related dysbiosis linked to Alzheimer’s and Parkinson’s disease. Animal studies demonstrate that probiotic strains such as Lactobacillus and Bifidobacterium can reduce neuroinflammation and improve cognitive markers, while fecal microbiota...